Gout

Detailed Overview

Gout is the most common form of inflammatory arthritis in adult men. It results from a mismatch between uric acid production and excretion—primarily renal underexcretion (90% of cases). The disease has distinct phases: asymptomatic hyperuricemia, acute flares, intercritical gout (symptom-free periods), and chronic tophaceous gout. Cardiovascular comorbidities are highly prevalent in gout patients, making holistic metabolic management essential alongside urate-lowering therapy.

Epidemiology & Demographics

Prevalence is approximately 3.9% in US adults. Striking male predominance (3-4:1 compared to females). Postmenopausal females are at increased risk due to loss of the uricosuric effect of estrogen. Peak age of onset is 40-50 years in men and >60 in women.

Etiological Mechanism

Driven by hyperuricemia (serum urate > 6.8 mg/dL). Caused by underexcretion of uric acid by the kidneys (primary or secondary to chronic kidney disease, diuretics) or overproduction (purine-rich diet, alcohol, myeloproliferative disorders, tumor lysis syndrome). Genetic polymorphisms in urate transporters (e.g., SLC2A9, ABCG2) strongly influence susceptibility.

Primary Causes

Renal impairment, thiazide and loop diuretics (decrease urate excretion), high intake of purines (red meat, shellfish), high fructose corn syrup, and excessive alcohol consumption (especially beer).

• Diet: High purine diet, fructose-sweetened beverages, and alcohol intake.
• Medications: Thiazide diuretics, low-dose aspirin, cyclosporine, and niacin increase serum urate.

When serum uric acid exceeds its physiologic saturation point (approx. 6.8 mg/dL at physiological pH and temperature), it precipitates as needle-shaped MSU crystals in avascular tissues (cartilage) and relatively colder peripheral joints. These crystals are phagocytosed by resident macrophages, triggering the NLR family pyrin domain containing 3 (NLRP3) inflammasome. This leads to the activation of caspase-1 and massive release of Interleukin-1β (IL-1β). IL-1β drives intense neutrophil influx, vasodilation, and erythema, manifesting as an acute gout flare. Chronic deposition forms foreign-body granulomas (tophi) causing bone erosions.

Characteristic Clinical Presentation

• Podagra: Rapid onset (often overnight) of exquisite, throbbing pain in the 1st metatarsophalangeal (MTP) joint. Even the weight of a bedsheet is intolerable.
• Joint Swelling and Erythema: The affected joint is massively swollen, dusky red, and warm to the touch, mimicking cellulitis.

Physical Examination Signs

• Tophi: Firm, chalky, subcutaneous nodules commonly found on the pinna of the ear, olecranon bursa, and Achilles tendon.
• Desquamation of the skin overlying the joint as the acute flare resolves.

• Urate Nephropathy: Deposition of urate crystals in the renal medullary interstitium, leading to chronic kidney disease.
• Joint Deformity: Chronic erosions leading to disabling osteoarthritis and loss of joint function.

Diagnostic Criteria & Guidelines

Gold standard is synovial fluid analysis showing negatively birefringent, needle-shaped monosodium urate crystals under polarized light microscopy. Clinically diagnosed using the 2015 ACR/EULAR criteria (score ≥8 based on clinical, lab, and imaging features).

Differential Diagnosis

• Septic Arthritis (must exclude via arthrocentesis)
• Pseudogout (CPPD crystal deposition)
• Cellulitis

Laboratory Tests & Biomarkers

• Synovial Fluid Analysis: WBC count 20,000 to 100,000/μL (mostly neutrophils), presence of MSU crystals.
• Serum Uric Acid: Often > 6.8 mg/dL, though may be normal during an acute flare due to IL-6 uricosuric effects.

Imaging Modalities & Findings

• Plain Radiography (X-ray):
• Dual-Energy CT (DECT):

• Acute Gout Flare
  Maximal inflammation within 12-24 hours, usually monoarticular.
• Intercritical Gout
  Symptom-free intervals between flares, though silent crystal deposition may continue.
• Chronic Tophaceous Gout
  Polyarticular involvement, continuous baseline pain, joint destruction, and visible tophi.

Second-Line & Adjunctive Therapy

Urate-Lowering Therapy (ULT - for chronic management): Allopurinol starting at 100 mg daily (50 mg in CKD stage 4+), titrated every 2-5 weeks up to 800 mg daily to achieve a target Serum Uric Acid < 6.0 mg/dL. Must use concomitant flare prophylaxis (Colchicine 0.6 mg daily) for the first 3-6 months of ULT.

Surgical & Procedural Management

Surgical excision of tophi is rarely indicated, usually reserved for intractable pain, nerve entrapment (e.g., carpal tunnel syndrome), or recurrent infection of tophi.

Recommended Lifestyle Changes

• Limit intake of high-fructose corn syrup, purine-rich meats (beef, lamb), and seafood.
• Avoid alcohol, specifically beer and spirits. Wine is less strongly associated.
• Weight loss in obese patients improves insulin resistance and renal urate excretion.

Patient Counseling & Advice

Emphasize that gout is a chronic, lifelong disease requiring continuous daily medication (ULT), even when pain-free, to dissolve existing crystals and prevent flares. Warn about the paradox that starting Allopurinol can initially trigger a flare.

Follow-Up & Monitoring Schedule

Check Serum Uric Acid every 2-4 weeks during ULT titration until target (<6.0 mg/dL) is reached, then monitor every 6 months. Monitor renal function and LFTs.

Preventive Strategies

Strict adherence to daily Allopurinol and lifestyle/dietary modifications. Switching antihypertensives from Thiazides to Losartan (which has mild uricosuric effects) if possible.

Excellent with compliance to ULT. Tophi can completely resolve, and flares can be eliminated. Poor prognosis is linked to cardiovascular comorbidities and severe medication non-adherence.